Last reviewed · How we verify
Angiotensin II Receptor Antagonists
Angiotensin II receptor antagonists block the binding of angiotensin II to AT1 receptors on blood vessels and other tissues, causing vasodilation and reducing blood pressure.
Angiotensin II receptor antagonists block the binding of angiotensin II to AT1 receptors on blood vessels and other tissues, causing vasodilation and reducing blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction.
At a glance
| Generic name | Angiotensin II Receptor Antagonists |
|---|---|
| Sponsor | Nara Medical University |
| Drug class | Angiotensin II receptor antagonist (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
These drugs selectively antagonize angiotensin II type 1 (AT1) receptors, preventing the hormone angiotensin II from exerting its vasoconstrictive and aldosterone-stimulating effects. By blocking AT1 receptor signaling, they reduce peripheral vascular resistance, lower blood pressure, and decrease sodium and water retention. This mechanism makes them effective for hypertension and heart failure management.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction
- Diabetic nephropathy
Common side effects
- Dizziness
- Hyperkalemia
- Cough
- Fatigue
- Hypotension
Key clinical trials
- Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
- The GUARDIAN Pilot Trial (NA)
- A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria (PHASE2)
- Vascular Intervention Strategies Trial for Alzheimer's (PHASE2)
- Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients (NA)
- Immune System in Diabetic Kidney Disease
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Angiotensin II Receptor Antagonists CI brief — competitive landscape report
- Angiotensin II Receptor Antagonists updates RSS · CI watch RSS
- Nara Medical University portfolio CI